EUROGIN 2024 | Methylation Testing Helps Global Strategy to Eliminate Cervical Cancer

The European Organization for the Study of Genital Infection and Oncology (EUROGIN) conference is an important academic conference in the interdisciplinary research fields of human papillomavirus (HPV) fundamentals, clinical, epidemiological, and behavioral studies worldwide. Its aim is to translate scientific and evidence-based research into clinical practice, accelerate the reduction of the burden and mortality rate of HPV related cancers.

The 2024 EUROGIN International Multidisciplinary HPV Conference was grandly held in Stockholm, Sweden from March 13th to 16th. This year's theme is "HPV Research Innovation and Global Cancer Solutions: An International Cooperation Conference.". The purpose of this conference is to promote joint discussions among academia, professional organizations, and patients, to transform research science into clinical practice, and to gather high-quality and innovative scientific plans and guidelines developed by outstanding international leaders.

The special report of the conference not only explores the prevention and treatment of HPV infection diseases such as cervical cancer, head and neck cancer, and anal cancer with HPV testing and vaccines, but also focuses on the clinical application of new technologies such as DNA methylation and vaginal self sampling in cervical cancer testing this year.

This conference held a total of 4 methylation themed events, including:

Session 1. Methylation markers as management tool in anal, vulvar, and cervical intraepithelial tumors;

Session 2. Methylation testing as indicators for cervical screening and diagnosis of cervical and non cervical HPV associated lesions (Indications for methylation testing in cervical screening and in the diagnosis of cervical and non cervical HPV associated lesions);

Session 3. Methylation I;

Session 4. Methylation II.

Dr. Liu Yuli, representing the clinical research team of CISPOLY, presented a report titled "A multicenter study on the accuracy of detecting PAX1/JAM3 double gene methylation in cervical scraping cells as a clinical predictor of cervical cancer" at the conference special session 4. This report is the only Chinese data sharing among 26 DNA methylation themed speeches, receiving high attention and enthusiastic discussion from international experts and scholars.

From 2022 to 2023, CISPOLY conducted a multicenter study on cervical cancer methylation outpatient screening with a population of 10000 people. The research results were unblinded for the first time at an international conference and partially shared. The PAX1/JAM3 dual gene methylation detection showed 88% sensitivity and 87% specificity in diagnosing CIN3+pathology, and its area under the receiver operating characteristic curve (AUC) was significantly better than cytology or Hr HPV detection. Clinical research results indicate that PAX1 has a high positive detection rate in cervical squamous cell carcinoma, while JAM3 has better detection performance in cervical adenocarcinoma and special cervical tumors. Therefore, PAX1/JAM3 dual gene methylation detection has high specificity, which can not only be used for high-risk HPV diversion, reduce vaginal referral rates, but also demonstrate excellent detection efficiency for non HPV related cervical cancer, and has excellent health economic potential.

After the speech, the experts at the venue put forward various opinions on topics such as PAX1/JAM3 methylation gene mining, reagent kit development and parameter setting, and future specimen cooperation research between Europe and China, creating a lively atmosphere.

As a high-tech enterprise focused on methylation and driven by innovation, CISPOLY focuses on evidence-based and clinical and academic research on methylation applications. Currently, it has conducted multiple prospective multicenter clinical trials and achieved rich data results. In the future, CISPOLY will actively promote the detection of PAX1/JAM3 dual gene methylation in cervical cancer products (trade name: Hegongkang CISCER) ?， The widespread application of NMPA certification, European CE certification, and UK UKCA certification in domestic and even international clinical practice, using innovative technologies to support the implementation of the global strategy to eliminate cervical cancer.

CISPOLY is a technology enterprise driven by innovative technology and with a focus on health. CISPOLY is a pioneer in the field of early diagnosis of gynecological tumors. With exclusive technology and patented biomarkers as the core, it has developed early diagnosis products for gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer, filling the gap in this field.

As women's attention to their own health becomes increasingly close, the women's health market will have great potential. In addition to the early screening and diagnosis product line for gynecological tumors, CISPOLY will also establish more product pipelines related to women's health in the future, creating a leading enterprise in technological innovation in the women's health market.